 The study drug LOVAZA improves the TCHDL ratio which is the strongest predictor of CHD events based on the 30,000 patient Interheart study noted above. LOVAZA has no hepatic P450 effects and for that matter no meaningful clinical adverse effects, making it advantageous for use in a population with multiple co-morbidities who are at risk for drug-drug interactions and have difficulty with medication adherence. Given the high incidence of insulin resistance among DHs predominately Latino CHD population, and strong lipid Harris et al, 1997; Davidson et al 2007 as well outcome data in CHD GISSI investigators, 1999 this agent has potential clinical utility in our population. 